Study details
Enrolling now
Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2
Stanford University
NCT IDNCT05833217ClinicalTrials.gov data as of Apr 2026
Target enrollment
55
Study length
about 2.6 years
Ages
18–80
Locations
2 sites in CA
What this study is about
Researchers are testing whether adipose tissue contributes to long COVID (PASC) by driving chronic inflammation or serving as a reservoir for the virus. The trial will also determine if obesity and insulin resistance are risk factors for PASC.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Steady State Plasma Glucose (SSPG) Test
- 2.Undergo Adipose Tissue Biopsy
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Rate of Inflammatory Gene Expression in Adipose Tissue, Triglyceride/HDL-cholesterol ratio
Procedures
biopsy, diagnostic